Data Insights

GLPG-5301 by Galapagos for Refractory Multiple Myeloma: Likelihood of Approval

GLPG-5301 is under clinical development by Galapagos and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase...

Data Insights

GLPG-5301 by Galapagos for Relapsed Multiple Myeloma: Likelihood of Approval

GLPG-5301 is under clinical development by Galapagos and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase...

Data Insights

GLPG-3667 by Galapagos for Systemic Lupus Erythematosus: Likelihood of Approval

GLPG-3667 is under clinical development by Galapagos and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...

Data Insights

GLPG-3667 by Galapagos for Ulcerative Colitis: Likelihood of Approval

GLPG-3667 is under clinical development by Galapagos and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - GLPG-3667 in Ulcerative Colitis

Data Insights

GLPG-3667 by Galapagos for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval

GLPG-3667 is under clinical development by Galapagos and currently in Phase I for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - GLPG-3667 in Plaque Psoriasis (Psoriasis Vulgaris)

Data Insights

GLPG-5201 by Galapagos for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

GLPG-5201 is under clinical development by Galapagos and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - GLPG-5201 in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

GLPG-5201 by Galapagos for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

GLPG-5201 is under clinical development by Galapagos and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - GLPG-5201 in Relapsed Chronic Lymphocytic Leukemia (CLL)

Data Insights

Filgotinib maleate by Galapagos for Giant Lymph Node Hyperplasia (Castleman's Disease): Likelihood of Approval

Filgotinib maleate is under clinical development by Galapagos and currently in Phase I for Giant Lymph Node Hyperplasia (Castleman's Disease)....

Likelihood of Approval and Phase Transition Success Rate Model - Filgotinib Maleate in Giant Lymph Node Hyperplasia (Castleman's Disease)